Literature DB >> 25233690

Association of gene variants in TLR4 and IL-6 genes with Perthes disease.

Sanja Srzentić, Vesna Spasovski, Dusko Spasovski, Zorica Zivković, Dragana Matanović, Zoran Bascarević, Zorica Terzić Supić, Maja Stojiljković, Teodora Karan-Djurasević, Biljana Stanković, Sonja Pavlović, Gordana Nikcević, Zoran Vukasinović.   

Abstract

INTRODUCTION: Perthes disease is idiopathic avascular osteonecrosis of the hip in children, with unknown etiology. Inflammation is present during development of Perthes disease and it is known that this process influences bone remodeling.
OBJECTIVE: Since genetic studies related to inflammation have not been performed in Perthes disease so far, the aim of this study was to analyze the association of frequencies of genetic variants of immune response genes, toll-like receptor 4 (TLR4) and interleukin-6 (IL-6), with this disease.
METHODS: The study cohort consisted of 37 patients with Perthes disease and 50 healthy controls. Polymorphisms of well described inflammatory mediators: TLR4 (Asp299Gly, Thr39911e) and 11-6 (G-174C, G-597A) were determined by polymerase chain reaction restriction fragment length polymorphism method. Results IL-6 G-174C and G-597A polymorphisms were in complete linkage disequilibrium. A statistically significant increase of heterozygote subjects for IL-6 G-174C/G-597A was found in controls in comparison to Perthes patient group (p = 0.047, OR = 2.49, 95% CI = 1.00-6.21). Also, the patient group for IL-6 G-174C/G-597A polymorphisms was not in Hardy-Weinberg equilibrium. No statistically significant differences were found between patient and control groups for TLR4 analyzed polymorphisms. A stratified analysis by the age at disease onset also did not reveal any significant difference for all analyzed polymorphisms. Conclusion Our study revealed that heterozygote subjects for the IL-6 G-174C/G-597A polymorphisms were significantly overrepresented in the control group than in the Perthes patient group. Consequently, we concluded that children who are heterozygous for these polymorphisms have a lower chance of developing Perthes disease than carriers of both homozygote genotypes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25233690

Source DB:  PubMed          Journal:  Srp Arh Celok Lek        ISSN: 0370-8179            Impact factor:   0.207


  6 in total

1.  Prevalence of Low Platelet Count and Identification of Associating Determinants and Genetic Polymorphism in Healthy Individuals of Upper Assam, India.

Authors:  Nasreen Sultan; Santanu Kumar Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2018-09-08       Impact factor: 0.900

2.  Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease—Serbian experience.

Authors:  Sanja Srzentić; Gordana Nikčević; Duško Spasovski; Zoran Baščarević; Zorica Živković; Zorica Terzic-Šupić; Dragana Matanović; Valentina Djordjević; Sonja Pavlović; Vesna Spasovski
Journal:  Eur J Pediatr       Date:  2015-03-11       Impact factor: 3.183

3.  Association of eNOS 27-bp VNTR, 894G>T and 786T>C polymorphisms with susceptibility to Legg-Calve-Perthes Disease in Iranian children.

Authors:  Mohammad Reza Azarpira; Mohammad Mahdi Ghilian; Mohammad Reza Sobhan; Masoud Mahdinezhad-Yazdi; Kazem Aghili; Hossein Ahrar; Hossein Neamatzadeh
Journal:  J Orthop       Date:  2019-02-26

4.  Comparative study of serum proteomes in Legg-Calve-Perthes disease.

Authors:  Ruiyu Liu; Lihong Fan; Longbin Yin; Kunzheng Wang; Wusheng Miao; Qichun Song; Xiaoqian Dang; Hang Gao; Chuanyi Bai
Journal:  BMC Musculoskelet Disord       Date:  2015-10-05       Impact factor: 2.362

5.  Interferon β protects against avascular osteonecrosis through interleukin 6 inhibition and silent information regulator transcript-1 upregulation.

Authors:  Kyoung Min Kim; Sajeev Wagle; Young Jae Moon; Sung Il Wang; Byung-Hyun Park; Kyu Yun Jang; Jung Ryul Kim
Journal:  Oncotarget       Date:  2017-12-16

Review 6.  Legg-Calvé-Perthes disease overview.

Authors:  Armando O Rodríguez-Olivas; Edgar Hernández-Zamora; Elba Reyes-Maldonado
Journal:  Orphanet J Rare Dis       Date:  2022-03-15       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.